Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
暂无分享,去创建一个
C. Wouters | T. Constantin | Navita L. Mallalieu | M. Rosenkranz | Y. Kimura | H. Huppertz | K. Schikler | W. Douglass | R. Joos | R. Cuttica | D. Milojevic | J. Hsu | C. Wells | S. Wimalasundera | I. Penadés